Search

Displaying results 8231 - 8240 of 10000 in total
  1. Drug

    SRN-101

    go.drugbank.com/drugs/DB33962
    Experimental

    SRN-101 is a biologic drug. … SRN-101 is under investigation in clinical trial NCT07826949 (A Phase 1 Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.).

  2. Drug

    BI 4060107

    go.drugbank.com/drugs/DB33963
    Experimental

    BI 4060107 is a small molecule drug. … BI 4060107 is under investigation in clinical trial NCT07827144 (A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)).

  3. Drug

    161Tb-PSMA-1

    go.drugbank.com/drugs/DB33964
    Experimental

    161Tb-PSMA-1 is a small molecule drug. 161Tb-PSMA-1 is under investigation in clinical trial NCT07828249 (Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal

  4. Drug

    Lm-LLO-TT

    go.drugbank.com/drugs/DB33966
    Experimental

    Lm-LLO-TT is a biologic drug. Lm-LLO-TT is under investigation in clinical trial NCT07828236 (PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA).

  5. Drug

    SGX-001

    go.drugbank.com/drugs/DB33968
    Experimental

    SGX-001 is a biologic drug. SGX-001 is under investigation in clinical trial NCT07826767 (Open-label Gene Therapy Study in p47-CGD).

  6. Drug

    JUR-003

    go.drugbank.com/drugs/DB33972
    Experimental

    JUR-003 is a small molecule drug. JUR-003 is under investigation in clinical trial NCT07824349 (JUR-003 in Adult Patients With Metastatic Prostate Cancer).

  7. Drug

    Bivalirudin

    go.drugbank.com/drugs/DB00006
    ApprovedInvestigational

    Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin.

    Products: ANGIOMAX® POLVO LIOFILIZADO PARA RECONSTRUIR A SOLUCIÓN INYECTABLE (50MG/ML), OBIVADIN 250 MG IV ENJEKSIYON/INFÜZYON IÇIN LIYOFILIZE TOZ, 1 ADET
  8. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    When combined together, Peginterferon alfa-2a and [DB00811] have been shown to achieve a SVR between 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment. … Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: Interferon Type I, Treatments for Hepatitis CProducts: PEGASYS 135 MCG/0.5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ŞIRINGA, 1 ADET, PEGASYS 135 MCG/0.5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ŞIRINGA, 4 ADET
  9. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. … [A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.

    Synonyms: t-PA, r-tPAProducts: ACTILYSE 20 MG FLAKON, 1 ADET, ACTILYSE 10 MG FLAKON, 1 ADET
  10. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.

    Categories: Interferon Type I, Cytochrome P-450 CYP1A2 InhibitorsProducts: WELLFERON INYECTABLE 5 MU/ML